Table 1 Clinico-pathologic data of participants
From: Immune landscape of the tumour microenvironment in Ethiopian breast cancer patients
Features | N (%) |
|---|---|
Age | |
younger (< 50) | 50 (61%) |
older (≥ 50) | 19 (23%) |
Unknown | 13 (16%) |
Pathologic Stage | |
Early (stage I & II) | 40 (48.8%) |
Advanced (stage I & II) | 27 (33%) |
Unknown | 15 (18.2%) |
Histological grade | |
G1 or G2 | 28 (34.1%) |
G3 | 54 (65.9%) |
Intrinsic subtype | |
luminal A | 28 (34.1%) |
luminal B | 15 (18.3%) |
HER2-enriched | 19 (23.2%) |
basal-like | 20 (24.4%) |
IHC Group | |
HR+ HER2− (luA-like) HR+ HER2+ (luB-like) | 41 (50.0) 22 (26.8) |
HR− HER2+ (HER2+) HR− HER2− (TNBC) | 7 (8.5) 12 (14.6) |